Sanofi Pays Up to $8B to Expand Regeneron Alliance With Four Long-Acting Drugs
SNY is trading near its 52-week low of $40.4 (2.3% above the low).
Summary
Sanofi will pay Regeneron up to $8B, including $1B upfront, to jointly develop four long-acting immunology therapies. The deal adds REGN20423, a clinical-stage long-acting IL-13 antibody, plus a long-acting IL-4xIL-13 bispecific and two preclinical antibodies to their existing alliance. This deepens a 20-year collaboration that produced Dupixent, now used by over 1.5 million patients. For Sanofi, the upfront payment is modest relative to its ~$99B market cap, but the total potential payout signals a major bet on long-acting biologics. Regeneron gains a large partner to fund development of its next-generation pipeline. Watch for further details on milestone structure and development timelines.
At the time of this announcement, SNY was trading at $41.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.7B. The 52-week trading range was $40.40 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.